Companies you'll love to work for

K36 Therapeutics

k36tx.com

K36 Therapeutics is focused on developing breakthrough therapies for cancer patients with unmet medical needs, particularly targeting multiple myeloma. Their lead candidate, KTX-1001, is a first-in-class selective inhibitor of the histone methyltransferase MMSET, which is overexpressed in a subset of multiple myeloma patients. This innovative approach aims to provide a targeted therapy that addresses the underlying causes of cancer, positioning K36 Therapeutics as a leader in the epigenetic modulation of oncogenic pathways.